NICHD Neonatal Research Network

NICHD 新生儿研究网络

• 批准号: 10682953
• 负责人: Ravi Mangal Patel
• 金额: $ 34.43万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-04-01 至 2030-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10682953
• 关键词: Address; Admission activity; Area; Asian; Biomedical Engineering; Black race; Blood Platelets; Boston; Bronchopulmonary Dysplasia; Caffeine; Caring; Centers for Disease Control and Prevention (U.S.); Cerebral Palsy; Cessation of life; Characteristics; Child; Child Health; Child health care; Childhood; Cities; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communicable Diseases; Conduct Clinical Trials; Development; Discipline of obstetrics; Enrollment; Ensure; Epidemiology; Ethics; Faculty; Family; Funding; Gynecology; Health system; Hemorrhage; Hispanic; Hospitals; Hour; Indiana; Individual; Infant; Infrastructure; Institution; International; Intervention; Lactation; Link; Live Birth; Measures; Medicine; Methodology; Mission; Multi-Institutional Clinical Trial; Multicenter Neonatal Research Network; National Institute of Child Health and Human Development; Necrotizing Enterocolitis; Neonatal; Neonatology; Neurophysiology - biologic function; Neurosciences; Newborn Infant; Observational Study; Outcome; Paper; Patients; Perinatal; Perinatal Epidemiology; Persons; Pharmacology; Platelet Transfusion; Population; Pregnancy; Productivity; Protocols documentation; Public Health Schools; Publications; Reproducibility; Research; Research Infrastructure; Research Personnel; Research Support; Research Training; Role; Services; Site; Talents; Technology; Testing; Translating; Underserved Population; United States National Institutes of Health; Universities; University Hospitals; Work; adverse outcome; autism spectrum disorder; biomarker development; biomedical informatics; biomedical referral center; clinical epidemiology; clinical infrastructure; cost; experience; extreme prematurity; follow-up; high risk; implementation science; improved; innovation; maternal risk; metropolitan; nutrition; participant enrollment; patient population; pediatric department; programs; protocol development; randomized trial; research facility; sociodemographics; success; transfusion medicine; unnecessary treatment; vaccine development

ABSTRACT In this renewal application, we highlight the ability, commitment and strengths of Emory University to continue its more than 3 decades of participation in the Eunice Kennedy Shriver NICHD Multicenter Neonatal Research Network (NRN). As the largest metropolitan city in the US with a single perinatal-referral center (Emory) and single academic children's health system (Children's Healthcare of Atlanta-CHOA), we have a large pool of high-risk admissions. Our center brings together 3 Emory-affiliated Atlanta hospitals: Grady Memorial Hospital, the largest hospital in Georgia with a focus on caring for underserved populations; Emory University Hospital Midtown, a high-volume delivery hospital and high-risk maternal center; and CHOA at Egleston, a quaternary referral center. These sites care for ~8,000 live-births and 1,800 neonatal admissions per year with a single group of neonatologists from the Pediatric Institute at Emory and CHOA. The inborn extremely preterm infants and their families comprise populations typically under-enrolled in neonatal trials (87% Black; 3% White) with diverse sociodemographic characteristics. The Emory center has deep expertise in clinical trials and epidemiology and a robust infrastructure for clinical research with strong institutional support. Dr. Ravi Patel will continue to lead the Emory site. He has been NRN PI since 2020 and served as site-PI for 6 randomized trials since 2012. He has nationally-recognized expertise in neonatal transfusion medicine, necrotizing enterocolitis, caffeine therapy and perinatal epidemiology. Additionally, Dr. Patel received scientific approval by the NRN Steering Committee for a randomized trial of platelet transfusion strategies that could be implemented in the upcoming cycle. Dr. Brenda Poindexter, Chief of the Division of Neonatology, is an established clinical investigator and internationally renowned researcher in neonatal nutrition. She will continue as alternate PI, bringing long-standing expertise and service to the NRN as Chair of the Protocol Subcommittee and as NRN PI for two prior institutions (Indiana University, 2006-2014 and Cincinnati Children's, 2014-2020). Dr. Nathalie Maitre will continue as follow-up PI, a role she began in 2016. She is a neuroscientist and established follow-up investigator with unique expertise in the development of quantitative measures of infant neural function. Drs. Barbara Stoll and Lucky Jain will continue as collaborators, along with a cadre of other talented investigators. Emory investigators led the two most cited NRN publications in the past decade. Additional strengths include: 1) A consolidated neonatology research infrastructure directed by the PI with 4.5 FTE of coordinators. This ensures prioritization of NRN studies and the ability to enroll 24/7; 2) Comprehensive follow-up program, with one of the highest follow-up rates in the NRN and 5 trials with 100% follow-up; 3) Close academic links to the Marcus Autism center, Emory-Georgia Tech biomedical engineering program, Rollins School of Public Health and CDC; 4) Strong institutional research strength: Department of Pediatrics ranked #4 in NIH funding; 5) Broad divisional engagement with the NRN: 10 current faculty have led or served as site-PI for NRN studies.

摘要 在这个更新的申请，我们强调的能力，承诺和埃默里大学的优势，继续 参与Eunice Kennedy Shriver NICHD多中心新生儿研究超过30年 网络（NRN）。作为美国最大的大都市，拥有单一的围产期转诊中心（埃默里）， 单一的学术儿童健康系统（Chilta-CHOA的儿童保健），我们有一个庞大的游泳池， 高风险入院我们的中心汇集了3个埃默里附属亚特兰大医院：格雷迪纪念医院， 格鲁吉亚最大的医院，重点照顾服务不足的人群;埃默里大学医院 市中心，一个高容量的分娩医院和高风险的孕产妇中心;和CHOA在埃格尔斯顿，一个四元 转诊中心。这些中心每年照料约8 000名活产婴儿和1 800名新生儿， 来自埃默里和CHOA儿科研究所的儿科专家组。先天性极早产儿 他们的家庭包括新生儿试验中通常登记不足的人群（87%黑人; 3%白色）， 不同的社会人口特征。埃默里中心在临床试验方面拥有深厚的专业知识， 流行病学和强大的临床研究基础设施，以及强大的机构支持。Ravi Patel博士 将继续领导埃默里实验室自2020年以来，他一直担任NRN PI，并担任6个随机化研究的研究中心PI 2012年以来的审判。他在新生儿输血医学、坏死性 小肠结肠炎，咖啡因治疗和围产期流行病学。此外，帕特尔博士还获得了科学批准， NRN指导委员会进行血小板输注策略的随机试验， 在即将到来的周期中。Brenda Poindexter博士，新生儿科主任，是一位成熟的临床 是国际知名新生儿营养研究者。她将继续担任候补私家侦探， 为NRN带来长期的专业知识和服务，作为议定书小组委员会主席和NRN 两个先前机构的PI（印第安纳州大学，2006-2014年和辛辛那提儿童，2014-2020年）。娜塔莉博士 Maitre将继续担任后续PI，这是她在2016年开始的角色。她是一名神经科学家， 在婴儿神经功能定量测量开发方面具有独特专长的研究者。Drs. 芭芭拉·斯托尔和幸运的贾恩将继续作为合作者，沿着还有其他一些有才华的调查人员。 埃默里大学的调查人员在过去十年中领导了两个引用最多的NRN出版物。其他优势包括： 1)一个由PI指导的综合性生殖医学研究基础设施，有4.5名全职协调员。这 确保NRN研究的优先顺序和全天候招募的能力; 2）全面的随访计划， NRN中随访率最高的试验之一，5项试验的随访率为100%; 3）与 马库斯自闭症中心，埃默里-佐治亚理工学院生物医学工程项目，罗林斯公共卫生学院 和CDC; 4）强大的机构研究实力：儿科系在NIH资助中排名第4; 5） 广泛的部门参与与NRN：10目前的教师领导或担任网站PI的NRN研究。